Aiml Resources (TSE:AIML)
:AIML
Top Page
Aiml Resources
(AIML)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.03
▼(-17.50% Downside)
Action:DowngradedDate:04/07/26
The score is primarily driven by very weak financial performance, including sharply declining revenue, deeply negative margins, and persistent cash burn. Technical signals are mixed but do not offset the weak fundamentals, and valuation is constrained by ongoing losses (negative P/E) with no dividend yield support.
Positive Factors
Low financial leverage
A low debt-to-equity (~0.11) reduces near-term solvency pressure and gives management more runway to execute turnarounds or seek non-debt financing. This modest leverage is a durable buffer against distress while cash flows are being restored.
Negative Factors
Steep recent revenue decline
A ~25% TTM revenue decline (and reported large negative revenue trend) erodes scale, reduces pricing leverage, and makes fixed-cost absorption harder. Sustained top-line shrinkage materially weakens long-term profitability prospects without clear revenue stabilization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A low debt-to-equity (~0.11) reduces near-term solvency pressure and gives management more runway to execute turnarounds or seek non-debt financing. This modest leverage is a durable buffer against distress while cash flows are being restored.
Read all positive factors
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.89M
Dividend YieldN/A
Average Volume (3M)377.83K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth-64.23%
EPS Growth18.42%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding253,987,750
10 Day Avg. Volume220,274
30 Day Avg. Volume377,826
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.95
Price to Sales (P/S)76.79
P/FCF Ratio-3.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aiml Resources Business Overview & Revenue Model
Company Description
Aiml Resources (AIML) is a technology-driven company specializing in artificial intelligence and machine learning solutions. The company operates primarily in sectors such as data analytics, predictive modeling, and automation, providing businesse...
How the Company Makes Money
null...
Aiml Resources Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.47K | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | -487.06K | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -6.43M | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -7.05M | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 1.63M | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 442.24K | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 181.57K | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 1.41M | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 252.74K | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | ||||||
| Free Cash Flow | -5.25M | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -5.24M | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -3.72K | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 3.83M | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Aiml Resources Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.05
Negative
Market Momentum
<0.01
Positive
51.51
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.51 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AIML.
Aiml Resources Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$14.18M | -11.57 | ― | ― | 16.04% | -455.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$30.71M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
42 Neutral | C$6.67M | -4.68 | ― | ― | ― | 81.01% | |
41 Neutral | C$7.77M | -5.12 | 6239.15% | ― | ― | 48.94% | |
40 Underperform | C$8.89M | -1.45 | -1143.80% | ― | -64.23% | 18.42% | |
| ― | C$13.14M | -21.40 | 527.45% | ― | ― | -67.11% |
* Healthcare Sector Average
TSE:AIML
Aiml Resources
0.04
-0.04
-50.00%
TSE:ADK
Diagnos
0.26
-0.02
-5.56%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.79
0.39
97.50%
TSE:UDOC
UniDoc Health Corp
0.09
-0.23
-71.88%
TSE:NARA
PanGenomic Health, Inc. Class A
0.48
0.27
126.19%
TSE:DMED
DiagnaMed Holdings Corp.
0.12
0.09
283.33%
Aiml Resources Corporate Events
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations Strikes ECG Tech Reseller Deal in European Digital Cardiology
Positive
Mar 31, 2026
AI/ML Innovations’ subsidiary Neural Cloud Solutions has signed a reseller agreement with a European digital health platform that specializes in cloud-based ECG and heart rate variability analytics. The partner will integrate and resell Neur...
Private Placements and FinancingRegulatory Filings and Compliance
AI/ML Innovations Raises $950,000 in First Tranche of Convertible Debenture Financing
Positive
Mar 27, 2026
AI/ML Innovations Inc. has closed the first tranche of a non-brokered private placement, issuing $950,000 in convertible debentures that can be converted into units at $0.05 per unit, each consisting of a common share and a warrant exercisable at ...
Business Operations and StrategyProduct-Related Announcements
AIML Subsidiary NeuralCloud Taps Baker Institute for AI-Powered ECG Research Deal
Positive
Mar 25, 2026
AI/ML Innovations’ subsidiary NeuralCloud Solutions has signed a research services agreement with Australia’s Baker Heart and Diabetes Institute to provide AI-powered ECG signal processing for a cardiovascular study on heart rate varia...
Private Placements and Financing
AI/ML Innovations Plans $3 Million Convertible Debenture Financing
Positive
Mar 13, 2026
AI/ML Innovations Inc., a global digital health technology company leveraging AI and neural networks to transform biometric data into clinical insights, is listed on the Canadian Securities Exchange, the OTCQB Venture Market and the Frankfurt Stoc...
Business Operations and StrategyProduct-Related Announcements
AIML’s Neural Cloud Taps Intelimed to Drive Cardiac AI Expansion in Latin America
Positive
Feb 24, 2026
AI/ML Innovations’ subsidiary Neural Cloud Solutions has signed a distribution agreement with Chile-based digital health provider Intelimed.ai to commercialize its MaxYield, CardioYield and Insight 360 cardiac software platforms across Latin...
Business Operations and StrategyProduct-Related Announcements
AIML’s NeuralCloud to Pilot AI-Powered ECG Reporting with Movesense
Positive
Feb 12, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a non-binding agreement with Finnish wearable sensor specialist Movesense to pilot AI-powered ECG and Holter reporting in real-world healthcare settings. The collaboration pairs...
Business Operations and StrategyProduct-Related Announcements
Neural Cloud Taps Commission Wolf to Build U.S. Cardiac AI Sales Network
Positive
Feb 10, 2026
AI/ML Innovations’ subsidiary Neural Cloud Solutions has hired U.S.-based sales recruiting firm Commission Wolf to build a network of independent representatives for its MaxYield and CardioYield cardiac diagnostics platforms. The effort targ...
Business Operations and StrategyExecutive/Board Changes
AI/ML Innovations Names Leading Cardiologist to Spearhead Clinical Strategy
Positive
Jan 28, 2026
AI/ML Innovations Inc. has appointed world-renowned cardiologist and research leader Dr. Paul Dorian as Medical Innovation Architect and Head of its Medical Advisory Board, succeeding Peter Kendall as the company advances clinical validation, regu...
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations’ NeuralCloud Partners with Movesense on AI-Driven Wearable ECG Solutions
Positive
Jan 20, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable d...
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations’ NeuralCloud Partners with Movesense on AI-Enabled Wearable ECG Solutions
Positive
Jan 20, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable E...
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations’ NeuralCloud Signs Deal to Deploy AI Cardiac Platform at Lakeshore Cardiology
Positive
Jan 8, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Lakeshore Cardiology to integrate its CardioYield AI visualization platform, powered by the proprietary MaxYield signal-processing e...
Business Operations and StrategyExecutive/Board Changes
AI/ML Innovations Taps Industry Veteran as COO to Drive AI Cardiac Platform Scale-Up
Positive
Jan 7, 2026
AI/ML Innovations Inc. has appointed healthcare and MedTech veteran Erik Suokas as Chief Operating Officer to lead day-to-day operations and drive the commercialization of its AI-driven cardiac platform. The move marks a shift from product develop...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.